Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Inhibition of CETP as a novel therapeutic strategy for reducing the risk of atherosclerotic disease.

European heart journal - 1 Jan 2007

Shah Prediman K

Abstract excerpt

Lowering low-density lipoprotein cholesterol (LDL-C) levels with statins is a proven strategy for reducing the risk of atherothrombotic cardiovascular disease (CVD). Yet, despite the success of statins in reducing cardiovascular event rates in at-risk patients, many will still experience further events. There is, therefore, a need to develop suitable therapies to reduce this residual risk. Low high-density...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Amides
Share to Cholesterol
Share to Cholesterol Ester Transfer Proteins

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Clinical Trials as Topic

Share to Coronary Artery Disease

Share to Esters

Share to Hydroxymethylglutaryl-CoA Reductase Inhibitors

Share to Sulfhydryl Compounds

Source

Identifiers

PMID: 17121756
DOI: 10.1093/eurheartj/ehl392

Genes

CETP

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Inhibition of CETP as a novel therapeutic strategy for reducing the risk of atherosclerotic disease.PMID 17121756Read ↗

Cholesteryl ester transfer protein inhibition in cardiovascular risk management: ongoing trials will end the confusion.Semantic proximity Read ↗

CETP-Inhibition and HDL-Cholesterol: A Story of CV Risk or CV Benefit, or Both.Semantic proximity Read ↗

[Can cardiovascular events be prevented by raising HDL cholesterol?].Semantic proximity Read ↗

CETP inhibitors and cardiovascular disease: Time to think againSemantic proximity Read ↗

Advances in the Study of the Antiatherogenic Function and Novel Therapies for HDLSemantic proximity Read ↗

Pharmacologic elevation of high-density lipoproteins: recent insights on mechanism of action and atherosclerosis protectionSemantic proximity Read ↗

Cholesteryl ester transfer protein: the controversial relation to atherosclerosis and emerging new biological roles.Semantic proximity Read ↗

Cholesteryl ester transfer protein polymorphisms, statin use, and their impact on cholesterol levels and cardiovascular events.Semantic proximity Read ↗

Novel and future lipid-modulating therapies for the prevention of cardiovascular diseaseSemantic proximity Read ↗

Association of CETP Gene Variants With Risk for Vascular and Nonvascular Diseases Among Chinese Adults.Semantic proximity Read ↗

Addressing dyslipidemic risk beyond LDL-cholesterol.Semantic proximity Read ↗

HDL, Atherosclerosis, and Emerging TherapiesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.